Clarity Receives $6.7 million R&D Tax Incentive Refund
Filed with ASX · · 1 page · English
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Clarity Corporate Presentation
- 50% recruitment milestone for NET diagnostic Phase II trial
- PROPELLER Trial Results
- Diagnostic prostate cancer trial reaches recruitment target
- Positive topline results from SAR-bisPSMA diagnostic trial
Later from Clarity Pharmaceuticals
- Theranostic prostate cancer trial advances to cohort 2
- Recruitment complete for Phase II prostate cancer trial
- Presentation at Jefferies Healthcare Conference
- Clarity expands supply of Cu-64 for Phase III trials
- COMBAT theranostic prostate cancer trial commences in the US
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals